GC Biopharma Corp announces that the US Food and Drug Administration has approved ALYGLO 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency.
GC Biopharma Corp announces that the US Food and Drug Administration has approved ALYGLO 10% Liquid, formerly referred to as “GC5107,” for the treatment of adult patients aged 17 years and older with primary humoral immunodeficiency.